This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Alpha-1 Antitrypsin Deficiency
  • /
  • Safety, Tolerability and Pharmacodynamic Effect of...
Clinical trial

Safety, Tolerability and Pharmacodynamic Effect of ARO-AAT (SEQUOIA)

Read time: 1 mins
Last updated:6th Mar 2022
Status: Active, not recruiting
Identifier: NCT03945292
Safety, Tolerability and Pharmacodynamic Effect of ARO-AAT (SEQUOIA)


Brief Summary:

The purpose of AROAAT2001 (SEQUOIA) is to evaluate the safety, efficacy and tolerability of multiple doses of the investigational product, ARO-AAT, administered subcutaneously to participants with alpha-1 antitrypsin deficiency (AATD).

Detailed Description:
Participants will be enrolled to receive multiple subcutaneous injections of ARO-AAT or placebo. Eligible participants will require a pre-dose biopsy completed as part of the study within the screening window. However, any participant with a biopsy result within 1 year of screening showing no fibrosis does not require a pre-dose biopsy. Only participants who have liver fibrosis will undergo a post-dose biopsy and may continue treatment in an open-label extension.


Study Type: Interventional (Clinical Trial)
Actual Enrollment: 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Placebo-Controlled, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Pharmacodynamic Effect of ARO-AAT in Patients With Alpha-1 Antitrypsin Deficiency (AATD) [SEQUOIA]
Actual Study Start Date: August 7, 2019
Estimated Primary Completion Date: July 13, 2022
Estimated Study Completion Date: July 13, 2022

Arms:
- Experimental: ARO-AAT
- Placebo Comparator: Placebo

Category Value
Study type(s) Interventional
Actual enrolment 40
Actual Study start date 07 August 2019
Estimated Study Completion Date 13 July 2022

View full details